Friday, 18 Jan 2019

You are here

Imaging Reveals Anatomical Focus of Inflammation in PMR

Two studies presented at ACR18 have used imaging to examine one of the key unanswered questions in polymyalgia rheumatica - what structures are the focus of inflammation in the disease – and demonstrated that peritendineal involvement is ubiquitous in and distinctive of PMR.

The culpable anatomical involvement in PMR remains controversial and elusive, despite equivalent clarity existing in most other similarly common rheumatic diseases. This ambiguity has limited not only the objective diagnosis in non-classical presentations but also the development of targeted and effective steroid-sparing therapies.

Dr. Fruth and colleagues, including Xenefon Baraliakos and Jurgen Braun, from Rheumazentrum Ruhrgebiet in Germany found peritendinous contrast enhancement differentiated the contrast-enhanced pelvic MRI scans of 40 patients with symptomatic PMR from 80 patients with other causes of pain. In particular, a characteristic pattern of bilateral involvement of peritendinitis of rectus femoris and adductor longus was able to discriminate patients with PMR with a sensitivity of 100% and a specificity of 95%.

In addition, Dr. Laporte and colleagues from Brest in France were able to identify similar myofascial lesions on MRI in a post-hoc analysis of the TENOR study, which examined tocilizumab in PMR patients. They showed that not only did all patients have these lesions, but that tocilizumab led to improvement of these lesions.

These studies build on previous work identifying analogous peritendineal changes on whole body MRI (https://ard.bmj.com/content/74/12/2188) and PET/MRI fusion (https://academic.oup.com/rheumatology/article-abstract/57/2/345/4600756). This establishment of a characteristic imaging appearance not only offers the potential of a useful diagnostic tool, but also provides the basis for further work into the pathophysiology of PMR and future therapeutic targets.

Abstract 318: https://acrabstracts.org/abstract/inflammatory-findings-detected-by-mri-at-entheseal-sites-in-the-pelvic-girdle-of-patients-with-polymyalgia-rheumatica-have-potential-for-a-diagnostic-test/

Abstract 2286: https://acrabstracts.org/abstract/myositis-and-fasciitis-by-magnetic-resonance-imaging-in-recent-onset-polymyalgia-rheumatica-and-effect-of-tocilizumab-therapy/

Add new comment

More Like This

Combo RA Treatment May Boost Risk for Serious Adverse Events

A current meta-analysis of safety and efficacy of combination bDMARD treatment in RA patients shows that combination treatments increase serious advese event (SAE) risks, and the risk for serious infections in particular.

Reassuring VTE Data for Tofacitinib

No significant differences in risk for venous thromboembolism (VTE) were seen in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) and those receiving tumor necrosis factor (TNF) inhibitors, analysis of administrative data showed.

CV Risks Similar in Systemic Sclerosis and Rheumatoid Arthritis

Interactions between disease-related inflammatory processes and the development of several morbidities have been well-studied in RA, particularly heart disease. This is not the case for the often-lethal SSc (estimated standardized mortality ratio between 2.5 and 4.0). Similarly, there are no studies comparing the most relevant comorbidities between SSc and RA.

PRAIRI Study - Can RA Be Prevented?

B-cell depletion may offer a means of delaying the onset of clinical arthritis in adults at high risk, according to the PRAIRI study - a proof-of-mechanism study in pre-clinical RA patients. 

Rheumatoid Lung Disease Imposes Significant Morbidity and Mortality

Insurance claims data were analyzed for the frequency of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA) and finds that although rare, its frequency increased over time and it is associated with a significant mortality rate. 

The study was done because RA-ILD has been shown to cause significant morbidity and mortality.